Adaptive Biotechnologies Corp
ADPT Nasdaq· Biological Products, (No Diagnostic Substances)
Last close · Oct 23, 2026
$25.51
KIRA · Stoqly’s AI analyst, in plain words
- Adaptive Biotechnologies Corp had $277M of revenue in fiscal 2025, up 54.8% on the year before. Over five years, revenue changed +23.0% a year on average.
- Its operating margin was −20.6%, up 70.2 pts: of every 100 in sales, about −21 is left after running the business.
- Adaptive Biotechnologies Corp lost $59.5M in fiscal 2025.
- Free cash flow was −$48.9M in fiscal 2025, −17.7% of revenue.
- Adaptive Biotechnologies Corp has $95.8M more cash than debt.
Market cap
$4.1B
P/E
—
Revenue
$277M
Net income
−$59.5M
Free cash flow
−$48.9M
Operating margin
−20.6%
Adaptive Biotechnologies Corp in 30 seconds · fiscal 2025
Are sales growing?
+54.8%
Yes. Sales grew 54.8% last year.
Does it make a profit?
−21.5%
No. It lost money last year.
Does profit turn into cash?
−17.7%
No. It spent more cash than it brought in.
How healthy are the accounts?
5 / 9
Mixed. It passes 5 of 9 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Adaptive Biotechnologies Corp does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Feb 26, 2026
- Legal name
- Adaptive Biotechnologies Corp
- CIK
- 0001478320
Adaptive Biotechnologies Corp · ADPT
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $154M | $185M | $170M | $179M | $277M |
| Revenue growth | 56.9% | 20.1% | −8.1% | 5.1% | 54.8% |
| Gross margin | 68.1% | 68.7% | 55.6% | 59.7% | 74.2% |
| Operating margin | −135.4% | −108.0% | −133.3% | −90.8% | −20.6% |
| Net income | −$207M | −$200M | −$225M | −$159M | −$59.5M |
| Net margin | −134.3% | −108.0% | −132.3% | −89.1% | −21.5% |
| Diluted EPS | −$1.48 | −$1.40 | −$1.56 | −$1.08 | −$0.39 |
| Cash | |||||
| Cash from operations | −$193M | −$184M | −$156M | −$95.2M | −$46.0M |
| Capital expenditure | $61.7M | $16.3M | $10.7M | $3.7M | $3.0M |
| Free cash flow | −$254M | −$200M | −$167M | −$98.9M | −$48.9M |
| FCF margin | −164.9% | −108.1% | −98.1% | −55.3% | −17.7% |
| Share count change | 7.0% | 1.5% | 1.3% | 1.9% | 3.1% |
| Debt and strength | |||||
| Cash and short-term investments | $353M | $498M | $346M | $222M | $227M |
| Debt incl. finance leases | — | $125M | $131M | $133M | $131M |
| Shareholders' equity | $604M | $464M | $308M | $203M | $219M |
| Current ratio | 3.5x | 5.1x | 4.7x | 2.9x | 3.3x |
| Interest coverage | — | −47.2x | −16.5x | −14.0x | −4.9x |
| Returns and quality | |||||
| Return on capital | — | −173.2% | −193.6% | −112.9% | −36.7% |
| Return on equity | −30.8% | −37.5% | −58.3% | −62.4% | −28.2% |
| Return on tangible equity | −43.5% | −59.2% | −122.2% | −198.6% | −60.7% |
| Piotroski F-score | 2 | 4 | 2 | 4 | 5 |
| Altman Z'' | −0.0 | −0.4 | −3.8 | −7.0 | −5.9 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$128M
11 insiders
Of sales under plans
73%
$94.2M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Adaptive Biotechnologies Corp · ADPT
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $25.51 a share, the company is worth $4.1B.
Source: SEC EDGAR XBRL filings (CIK 0001478320). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.